In a report released today, Sean Kim PhD from JonesTrading maintained a Hold rating on Landos Biopharma (LABP – Research Report). The company’s shares closed today at $0.27.
Kim PhD covers the Healthcare sector, focusing on stocks such as Concert Pharma, Satsuma Pharmaceuticals, and Ocuphire Pharma. According to TipRanks, Kim PhD has an average return of -10.9% and a 27.78% success rate on recommended stocks.
Landos Biopharma has an analyst consensus of Hold, with a price target consensus of $3.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $15.00 and a one-year low of $0.22. Currently, Landos Biopharma has an average volume of 260.1K.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LABP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need.
